Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia

Brain

Volumn 134, Issue 12, 2011, Pages 3613-3628

  Zou, Shiping ^a   Fitting, Sylvia ^a   Hahn, Yun Kyung ^a   Welch, Sandra P ^a   El Hage, Nazira ^a   Hauser, Kurt F ^a   Knapp, Pamela E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AIDS; astroglia; microglia; neurodegenerative disorders; neuroinflammation

Indexed keywords

3 NITROTYROSINE; GLUTAMIC ACID; MORPHINE; MU OPIATE RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL CONTACT; CELL TYPE; COCULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; EMBRYO; GLIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MICROGLIA; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 83755224872     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr281     Document Type: Conference Paper

References (110)

1. Aksenova MV, Aksenov MY, Adams SM, Mactutus CF, Booze RM. Neuronal survival and resistance to HIV-1 Tat toxicity in the primary culture of rat fetal neurons. Exp Neurol 2009; 215: 253-63.
2. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE. The effects of illicit drugs on the HIV infected brain. Front Biosci 2008; 13: 1294-307. (Pubitemid 351594711)
3. Anthony IC, Norrby KE, Dingwall T, Carnie FW, Millar T, Arango JC, et al. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain 2010; 133: 3685-98.
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99. (Pubitemid 350059308)
5. Bakalkin G, Watanabe H, Jezierska J, Depoorter C, Verschuuren-Bemelmans C, Bazov I, et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet 2010; 87: 593-603.
6. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90: 7941-5. (Pubitemid 23260830)
7. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. J Neuroimmune Pharmacol 2006; 1: 182-91. (Pubitemid 44257492)
8. Bell J, Arango JC, Robertson R, Brettle RP, Leen C, Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 2002; 31: S35-42. (Pubitemid 35190557)
9. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 2011; In Press.
10. Bokhari SM, Hegde R, Callen S, Yao H, Adany I, Li Q, et al. Morphine Potentiates Neuropathogenesis of SIV Infection in Rhesus Macaques. J Neuroimmune Pharmacol 2011; In Press.
11. Bokhari SM, Yao H, Bethel-Brown C, Fuwang P, Williams R, Dhillon NK, et al. Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 2009; 1-10.
12. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-associated dementia. Neurology 1998; 50: 1814-20. (Pubitemid 28283257)
13. Brake DA, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990; 111: 1275-81.
14. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin TM, Chauhan A, Ried R, et al. Morphine Increases astroglial and microglial activation in the brains of conditional HIV-Tat transgenic mice. Glia 2008; 56: 1414-27.
15. Buch SK, Khurdayan VK, Lutz SE, Knapp PE, El-Hage N, Hauser KF. Glial-restricted precursors: Patterns of expression of opioid receptors and relationship to HIV-1 Tat and morphine susceptibility in vitro. Neuroscience 2007; 146: 1546-54. (Pubitemid 46783210)
16. Burbassi S, Sengupta R, Meucci O. Alterations of CXCR4 function in mu-opioid receptor-deficient glia. Eur J Neurosci 2010; 32: 1278-88.
17. Burdo TH, Katner SN, Taffe MA, Fox HS. Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol 2006; 1: 41-9. (Pubitemid 44257499)
18. Campbell GR, Watkins JD, Loret EP, Spector SA. Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C Tat proteins. AIDS Res Hum Retroviruses 2010; 27: 647-54.
19. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50: 773-8.
20. Cepeda C, Andre VM, Yamazaki I, Wu N, Kleiman-Weiner M, Levine MS. Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci 2008; 27: 671-82. (Pubitemid 351239295)
21. Chao CC, Gekker G, Sheng WS, Hu S, Tsang M, Peterson PK. Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther 1994; 269: 198-203. (Pubitemid 24143254)
22. Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, Ma M, et al. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 1998; 82: 97-106.
23. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002; 59: 1563-7. (Pubitemid 35387063)
24. Chuang RY, Suzuki S, Chuang TK, Miyagi T, Chuang LF, Doi RH. Opioids and the progression of simian AIDS. Front Biosci 2005; 10: 1666-77. (Pubitemid 40529029)
25. Dahan A, Sarton E, Teppema L, Olievier C, Nieuwenhuijs D, Matthes HW, et al. Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice. Anesthesiology 2001; 94: 824-32. (Pubitemid 32429753)
26. Donahoe RM, Falek A. Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS. Adv Biochem Psychopharmacol 1988; 44: 145-58.
27. Donahoe RM, O'Eil SP, Marsteller FA, Novembre FJ, Anderson DC, Lankford-Turner P, et al. Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model. J Acquir Immune Defic Syndr 2009; 50: 241-9.
28. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83: 77-87. (Pubitemid 28280954)
29. Dougherty RH, Skolasky RL Jr, McArthur JC. Progression of HIV-associated dementia treated with HAART. AIDS Read 2002; 12: 69-74. (Pubitemid 34202705)
30. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, et al. Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2 + )](i), NF-kappaB trafficking and transcription. PLoS ONE 2008; 3: e4093.
31. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF. Synergistic increases in intracellular Ca2 + , and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 2005; 50: 91-106. (Pubitemid 40695264)
32. El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunology 2006a; 178: 9-16. (Pubitemid 44307341)
33. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed J, et al. HIV Tat1-72 and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006b; 53: 132-46.
34. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44. (Pubitemid 46011997)
35. Eugenin EA, King JE, Hazleton JE, Major EO, Bennett MV, Zukin RS, et al. Differences in NMDA receptor expression during human development determine the response of neurons to HIV-tat-mediated neurotoxicity. Neurotox Res 2011; 19: 138-48.
36. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999; 9: 209-17. (Pubitemid 29157710)
37. Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, et al. Interactive co-morbidity between opioid drugs of abuse and HIV-1 Tat: Chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010; 177: 1397-410.
38. Freese A, DiFiglia M, Koroshetz WJ, Beal MF, Martin JB. Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. Brain Res 1990; 521: 254-64. (Pubitemid 20208760)
39. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38: 755-62.
40. Goody RJ, Martin KM, Goebel SM, Hauser KF. Dynorphin A toxicity in striatal neurons via an a-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor mechanism. Neuroscience 2003; 116: 807-16. (Pubitemid 36160575)
41. Gupta S, Knight AG, Knapp PE, Hauser KF, Keller JN, Bruce-Keller AJ. HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antiporter. Neurosci Lett 2010; 485: 233-6.
42. Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, et al. Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 2007; 13: 195-202. (Pubitemid 47053787)
43. Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, et al. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 2001; 102: 555-63. (Pubitemid 32171876)
44. Haigwood NL. Predictive value of primate models for AIDS. AIDS Rev 2004; 6: 187-98. (Pubitemid 40227880)
45. Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, et al. Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res 2005; 8: 63-80.
46. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y, et al. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007; 100: 567-86. (Pubitemid 46095610)
47. Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, et al. HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia 2009; 57: 194-206.
48. Haughey NJ, Steiner J, Nath A, McArthur JC, Sacktor N, Pardo C, et al. Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci 2008; 13: 5120-30. (Pubitemid 351599662)
49. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 2002; 42: 829-36. (Pubitemid 34520444)
50. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 2005; 191: 886-9. (Pubitemid 40349803)
51. Kapasi AA, Gibbons N, Mattana J, Singhal PC. Morphine stimulates mesangial cell TNF-alpha and nitrite production. Inflammation 2000; 24: 463-76. (Pubitemid 30452554)
52. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 2005; 12 (Suppl. 1): 878-92. (Pubitemid 41038393)
53. Kopnisky KL, Bao J, Lin YW. Neurobiology of HIV, psychiatric and substance abuse comorbidity research: workshop report. Brain Behav Immun 2007; 21: 428-41. (Pubitemid 46541662)
54. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis 2010; 37: 542-8.
55. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005; 111: 194-213. (Pubitemid 40909736)
56. Kruman II, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 1998; 154: 276-88. (Pubitemid 29044201)
57. Kumar R, Orsoni S, Norman L, Verma AS, Tirado G, Giavedoni LD, et al. Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques. Virology 2006; 354: 192-206. (Pubitemid 44441512)
58. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 2006; 12: 100-7. (Pubitemid 44574601)
59. Li J, Bentsman G, Potash MJ, Volsky DJ. Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection. BMC Neurosci 2007; 8: 31.
60. Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 2008; 28: 12190-8.
61. Li Y, Merrill JD, Mooney K, Song L, Wang X, Guo CJ, et al. Morphine enhances HIV infection of neonatal macrophages. Pediatr Res 2003; 54: 282-8. (Pubitemid 36918165)
62. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 2000; 6: 1380-7. (Pubitemid 32001023)
63. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998; 54: 321-6. (Pubitemid 28171797)
64. Ma M, Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virology 1997; 71: 2495-9. (Pubitemid 27078635)
65. Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Fernandez SF, Schwartz SA, et al. Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res 2005; 3: 277-88. (Pubitemid 41052427)
66. Malik S, Khalique H, Buch S, Seth P. A growth factor attenuates HIV-1 Tat and morphine induced damage to human neurons: implication in HIV/AIDS-drug abuse cases. PLoS ONE 2011; 6: e18116.
67. Mao L, Wang JQ. Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons. Brain Res Mol Brain Res 2001; 86: 125-37. (Pubitemid 32124766)
68. Marcario JK, Riazi M, Adany I, Kenjale H, Fleming K, Marquis J, et al. Effect of morphine on the neuropathogenesis of SIVmac infection in Indian Rhesus Macaques. J Neuroimmune Pharmacol 2008; 3: 12-25.
69. Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ 2005; 12 (Suppl. 1): 893-904. (Pubitemid 41030604)
70. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003; 9: 205-221. (Pubitemid 36656454)
71. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A 2000; 97: 8075-80. (Pubitemid 30460775)
72. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, Spitzer P, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 2008; 194: 62-9.
73. Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008; 63: 366-76. (Pubitemid 351499866)
74. Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes: A hit and run phenomenon. J Biol Chem 1999; 274: 17098-102.
75. Noel RJ Jr, Kumar A. Virus replication and disease progression inversely correlate with SIV tat evolution in morphine-dependent and SIV/SHIV-infected Indian rhesus macaques. Virology 2006; 346: 127-38. (Pubitemid 43254705)
76. Noel RJ Jr, Marrero-Otero Z, Kumar R, Chompre-Gonzalez GS, Verma AS, Kumar A. Correlation between SIV Tat evolution and AIDS progression in cerebrospinal fluid of morphine-dependent and control macaques infected with SIV and SHIV. Virology 2006; 349: 440-52. (Pubitemid 43782884)
77. Nosheny RL, Bachis A, Acquas E, Mocchetti I. Human immunodeficiency virus type 1 glycoprotein gp120 reduces the levels of brain-derived neurotrophic factor in vivo: potential implication for neuronal cell death. Eur J Neurosci 2004; 20: 2857-64. (Pubitemid 40007279)
78. Nosheny RL, Bachis A, Aden SA, De Bernardi MA, Mocchetti I. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J Neurobiol 2006; 66: 1311-21. (Pubitemid 44713810)
79. Park Y, Ma T, Tanaka S, Jang C, Loh HH, Ko KH, et al. Comparison of G-protein activation in the brain by mu-, delta-, and kappa-opioid receptor agonists in mu-opioid receptor knockout mice. Brain Res Bull 2000; 52: 297-302. (Pubitemid 30365033)
80. Perez-Casanova A, Noel RJ Jr, Rivera-Amill V, Husain K, Kumar A. Morphine-mediated deterioration of oxidative stress leads to rapid disease progression in SIV/SHIV-infected macaques. AIDS Res Hum Retroviruses 2007; 23: 1004-7. (Pubitemid 47492341)
81. Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, et al. Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci 2010; 30: 14153-64.
82. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998; 83: 63-9. (Pubitemid 28280952)
83. Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 2008; 28: 10010-6.
84. Riedel D, Ghate M, Nene M, Paranjape R, Mehendale S, Bollinger R, et al. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India. J Neurovirol 2006; 12: 34-8.
85. Rivera-Amill V, Noel RJ Jr, Garcia Y, Rivera I, Iszard M, Buch S, et al. Accelerated evolution of SIV env within the cerebral compartment in the setting of morphine-dependent rapid disease progression. Virology 2010; 398: 201-7.
86. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 2003; 24: 116-21. (Pubitemid 36263094)
87. Roy S, Charboneau RG, Barke RA, Loh HH. Role of mu-opioid receptor in immune function. Adv Exp Med Biol 2001; 493: 117-26. (Pubitemid 34020219)
88. Rumbaugh JA, Steiner J, Sacktor N, Nath A. Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther 2008; 2: 271-80.
89. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D, et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem 1997; 272: 11313-20. (Pubitemid 27184133)
90. Ruzicka BB, Fox CA, Thompson RC, Meng F, Watson SJ, Akil H. Primary astroglial cultures derived from several rat brain regions differentially express m, d and k opioid receptor mRNA. Molec Brain Res 1995; 34: 209-20.
91. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8: 136-42. (Pubitemid 34520894)
92. Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res 2000; 111: 14-23. (Pubitemid 30213883)
93. Sheng WS, Hu S, Gekker G, Zhu S, Peterson PK, Chao CC. Immunomodulatory role of opioids in the central nervous system. Arch Immunol Ther Exp (Warsz) 1997; 45: 359-66. (Pubitemid 28098862)
94. Silvestri G. AIDS pathogenesis: A tale of two monkeys. J Med Primatol 2008; 37 (Suppl. 2): 6-12.
95. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, et al. Apoptotic death of striatal neurons induced by HIV-1 Tat and gp120: differential involvement of caspase-3 and endonuclease G. J Neurovirol 2004; 10: 141-51. (Pubitemid 38868152)
96. Singh IN, Goody RJ, Goebel SM, Martin KM, Knapp PE, Marinova Z, et al. Dynorphin A (1-17) induces apoptosis in striatal neurons in vitro through alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor-mediated cytochrome c release and caspase-3 activation. Neuroscience 2003; 122: 1013-23. (Pubitemid 37485851)
97. Song L, Nath A, Geiger JD, Moore A, Hochman S. Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site. J Neurovirol 2003; 9: 399-403. (Pubitemid 36874714)
98. Stiene-Martin A, Knapp PE, Martin K, Gurwell JA, Ryan S, Thornton SR, et al. Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo. Glia 2001; 36: 78-88.
99. Sultana S, Li H, Puche A, Jones O, Bryant JL, Royal W. Quantitation of parvalbumin + neurons and human immunodeficiency virus type 1 (HIV-1) regulatory gene expression in the HIV-1 transgenic rat: effects of vitamin A deficiency and morphine. J Neurovirol 2010; 16: 33-40.
100. Turchan-Cholewo J, Dimayuga FO, Ding Q, Keller JN, Hauser KF, Knapp PE, et al. Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 2008; 86: 2100-10.
101. Turchan-Cholewo J, Dimayuga FO, Gupta S, Keller JN, Knapp PE, Hauser KF, et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009; 108: 202-15.
102. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, Peng X, et al. Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 2006; 23: 109-19. (Pubitemid 43922460)
103. Valentine LE, Watkins DI. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol 2008; 16: 605-11.
104. Vaysse PJ, Zukin RS, Fields KL, Kessler JA. Characterization of opioid receptors in cultured neurons. J Neurochem 1990; 55: 624-31. (Pubitemid 120021638)
105. Wadia RS, Pujari SN, Kothari S, Udhar M, Kulkarni S, Bhagat S, et al. Neurological manifestations of HIV disease. J Assoc Physicians India 2001; 49: 343-8.
106. Wang Z, Pekarskaya O, Bencheikh M, Chao W, Gelbard HA, Ghorpade A, et al. Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. Virology 2003; 312: 60-73. (Pubitemid 36918460)
107. Wang Z, Trillo-Pazos G, Kim S-Y, Canki M, Morgello S, Sharer LR, et al. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol 2004; 10: 25-32. (Pubitemid 38325090)
108. Wong K, Sharma A, Awasthi S, Matlock EF, Rogers L, Van Lint C, et al. HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. J Biol Chem 2005; 280: 9390-9. (Pubitemid 40409632)
109. Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 2009; 5.
110. Yepthomi T, Paul R, Vallabhaneni S, Kumarasamy N, Tate DF, Solomon S, et al. Neurocognitive consequences of HIV in southern India: A preliminary study of clade C virus. J Int Neuropsychol Soc 2006; 12: 424-30. (Pubitemid 43970908)